The Association of Community Cancer Centers (ACCC), Hematology/Oncology Pharmacy Association (HOPA), National
Community Oncology Dispensing Association, Inc. (NCODA), and Oncology Nursing Society (ONS) have collaborated in gathering
information for and developing this patient education guide. This guide represents a brief summary of the medication derived from
information provided by the drug manufacturer and other resources. This guide does not cover all existing information related to the
possible uses, directions, doses, precautions, warnings, interactions, adverse effects, or risks associated with this medication and should
not substitute for the advice of a qualified healthcare professional. Provision of this guide is for informational purposes only and does
not constitute or imply endorsement, recommendation, or favoring of this medication by ACCC, HOPA, NCODA, or ONS, who assume
no liability for and cannot ensure the accuracy of the information presented. The collaborators are not making any representations with
respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual
consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a
qualified healthcare professional.
Oral Chemotherapy Education (OCE) sheets are provided as a free educational resource for patients with cancer in need of
concise, easy-to-understand information about oral cancer drugs. Healthcare providers are permitted to copy and distribute the sheets to
patients as well as direct patients to the OCE website for information. However, commercial reproduction or reuse, as well as rebranding
or reposting of any type, are strictly prohibited without permission of the copyright holder. Please email permission requests and licensing
inquiries to Contact@NCODA.org.
Cookies are required to agree to our terms of service. We only use this cookie to grant access to our library.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation.
Boehringer Ingelheim is one of the world’s top 20 pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with approximately 50,000 employees. Since its founding in 1885, the company has remained family-owned and today creates value through innovation for three business areas including human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.
Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and their families. Our employees create and engage in programs that strengthen our communities. Please visit our website to learn more about how we make more health for more people through our Corporate Social Responsibility initiatives.
In 2016, Boehringer Ingelheim achieved net sales of about $17.6 billion (15.9 billion euros). R&D expenditure corresponds to 19.6 percent of its net sales.
TESARO is a biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. We see new possibilities to responsibly develop and commercialize innovative treatments where others may not. Relationships are vital to the success of our business, and we are committed to being a trusted partner to the cancer community.
TESARO recognizes the importance of optimizing patient care and outcomes by providing people bravely facing cancer with accurate, informative, and relevant product education materials. Patients will directly benefit from the most updated product information, which will improve patient safety, side effect management and adherence.
At Helsinn, our vision is to help people with cancer get the most out of every day. We are committed to making everything we do - from the products we choose to license to the exacting standards we apply as a pharmaceutical manufacturer - count towards the best supportive care for cancer patients. Our mission is to bring respect, integrity and quality to our products, services, and all that we do to improve the health and quality of life in every person affected by cancer.
Exelixis, Inc. was founded and incorporated in 1994, and we are currently based in South San Francisco, California. Exelixis, from the Greek word for “evolution,” is a biopharmaceutical company committed to the discovery, development and commercialization of new medicines to improve care and outcomes for people with cancer. Over the past fifteen years, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounds, cabozantinib and cobimetinib, tells the story of our evolution as a company. Each of these compounds was discovered in our own laboratories and advanced by us into clinical development.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.
Collaborations of all kinds – with partners in science, academia, business and local communities – are central to our work. Partnerships enhance our ability to develop innovative medicines and deliver them to people as efficiently as possible.
Pharmacyclics is an AbbVie company based in Silicon Valley, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is great unmet medical need. We seek to discover innovative therapies to improve standards of care and strive to help our patients rediscover the Magic of Normal